AnaptysBio, Inc. (NASDAQ:ANAB) Director Buys $842,177.28 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc bought 65,184 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the transaction, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock. The stock was bought at an average cost of $12.95 per share, for a total transaction of $86,065.70.

AnaptysBio Trading Up 9.3 %

Shares of ANAB stock opened at $14.60 on Friday. The company has a market cap of $444.26 million, a P/E ratio of -2.40 and a beta of -0.02. The firm has a fifty day moving average price of $19.75 and a 200 day moving average price of $28.43. AnaptysBio, Inc. has a 12 month low of $12.51 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, equities analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Hedge Funds Weigh In On AnaptysBio

Hedge funds have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after buying an additional 43,598 shares in the last quarter. Ensign Peak Advisors Inc lifted its position in AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock valued at $1,898,000 after acquiring an additional 32,313 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in AnaptysBio by 202.8% in the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after acquiring an additional 36,300 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ANAB. Guggenheim dropped their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Truist Financial dropped their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. UBS Group increased their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. dropped their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Finally, HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $52.00 to $19.00 in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.